Comparison of the Efficacy and Safety of Apixaban and Warfarin in the Prevention of Stroke in Patients With Non-valvular Atrial Fibrillation: A Meta-Analysis.
apixaban
atrial fibrillation
meta-analysis
stroke
warfarin
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
accepted:
06
08
2022
entrez:
22
9
2022
pubmed:
23
9
2022
medline:
23
9
2022
Statut:
epublish
Résumé
Atrial fibrillation is an irregular heart rhythm, and it is one of the most common cardiac arrhythmias. It is associated with a five times increase in the risk of stroke. Anti-coagulants are prescribed routinely to prevent strokes, especially in patients with atrial fibrillation for many years decreasing the risk of stroke among patients with atrial fibrillation. Non-vitamin K oral anticoagulants especially apixaban and rivaroxaban are frequently used and they are considered to be safe and more effective than warfarin. The aim of this meta-analysis is to compare the efficacy and safety of apixaban and warfarin in preventing stroke among patients with non-valvular arterial fibrillation. The current meta-analysis was conducted using the guidelines established by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). A systematic search was done using databases, including PubMed, EMBASE, and Cochrane Library, with no restrictions on language and year of publication. The current meta-analysis included randomized control trials and non-randomized control trials (prospective and retrospective cohort studies) comparing the efficacy and safety of apixaban and warfarin in preventing stroke in patients with non-valvular atrial fibrillation. The primary efficacy outcome was stroke or systemic embolism while the primary safety outcome was major bleeding events. Overall, nine articles were included in the current meta-analysis with a pooled sample size of 267998 patients with non-valvular atrial fibrillation. The administration of apixaban was associated with a significant decrease in stroke or systemic embolism (RR: 0.77, 95% CI: 0.67-0.90) and major bleeding events (RR=0.63, 95% CI: 0.58-0.68) as compared to warfarin. However, no significant difference was reported in all-cause mortality (RR=0.80, 95% CI: 0.30-2.14) between the two groups. The current meta-analysis concluded that apixaban, compared to warfarin in patients with non-valvular atrial fibrillation showed a reduction in stroke and systemic embolism. Apixaban has also a better safety profile in terms of reduction in overall major bleeding events.
Identifiants
pubmed: 36134060
doi: 10.7759/cureus.27838
pmc: PMC9481239
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e27838Informations de copyright
Copyright © 2022, Memon et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Can J Cardiol. 2016 Oct;32(10):1170-1185
pubmed: 27609430
Curr Med Res Opin. 2018 Sep;34(9):1627-1634
pubmed: 29772946
Ther Clin Risk Manag. 2015 Jun 24;11:967-77
pubmed: 26150723
J Manag Care Spec Pharm. 2018 Nov;24(11):1116-1127
pubmed: 30212268
Am J Cardiol. 2004 Oct 1;94(7):947-51
pubmed: 15464686
Front Cardiovasc Med. 2021 Oct 18;8:752468
pubmed: 34733897
JAMA. 2001 May 9;285(18):2370-5
pubmed: 11343485
Circulation. 2016 Aug 23;134(8):589-98
pubmed: 27496855
N Engl J Med. 2011 Sep 8;365(10):883-91
pubmed: 21830957
BMJ. 2016 Jun 16;353:i3189
pubmed: 27312796
Cardiol Res Pract. 2019 Jul 07;2019:6419147
pubmed: 31360545
J Am Heart Assoc. 2016 May 20;5(5):
pubmed: 27207998
Res Pract Thromb Haemost. 2019 Jun 17;3(4):674-683
pubmed: 31624787
Thromb Haemost. 2017 Jun 2;117(6):1072-1082
pubmed: 28300870
Ann Intern Med. 2007 Jun 19;146(12):857-67
pubmed: 17577005
Circulation. 2014 Dec 2;130(23):2071-104
pubmed: 24682348
N Engl J Med. 2011 Sep 15;365(11):981-92
pubmed: 21870978
Eur Heart J. 2017 Mar 21;38(12):907-915
pubmed: 27742807
N Engl J Med. 2013 Nov 28;369(22):2093-104
pubmed: 24251359
BMJ. 2017 Feb 10;356:j510
pubmed: 28188243
Heart. 2016 Jul 1;102(13):1036-43
pubmed: 26888572
JAMA Cardiol. 2016 Sep 1;1(6):673-81
pubmed: 27463942
Adv Hematol. 2020 May 23;2020:3890706
pubmed: 32528538
Stroke. 1991 Aug;22(8):983-8
pubmed: 1866765
Stroke. 2018 Jan;49(1):98-106
pubmed: 29167388